Key facts
- Maverick Medical AI’s last known valuation is $13.7M (Feb 2025).
- It has raised $11.5M; the latest was Seed Round ($10.4M) in Feb 2025.
- Notable investors include MassChallenge, Innovation Authority, Cannell Capital, Ariel Maislos, Daniel Rudensky — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Maverick Medical AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Maverick Medical AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maverick Medical AI
Developer of a real-time autonomous medical coding platform designed to detect risk factors in medical records. The company's proprietary deep-learning and artificial intelligence technology use the textual data available in specialist reports to analyze patients' clinical status according to their risk factors and accurately estimate the probability of future risk factors for chronic conditions, it maximizes reimbursements and creates efficiencies between point of care and revenue cycle, in real-time and with an unmatched direct-to-bill rate, providing healthcare providers with valuable data for more effective diagnoses, risk profiling, and prediction.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2017
- Employees
- 25
- Website
- maverick-ai.com/
- Ownership
- Privately Held (backing)
Maverick Medical AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maverick Medical AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maverick Medical AI in its N-PORT filings yet. We sweep new filings monthly.